Written by Jane Aubrey
The biotechnology sector is closely watching the regulatory landscape this August, with several key Prescription Drug User Fee Act (PDUFA) dates poised to influence market dynamics and patient care. Among the most anticipated decisions is the potential approval of Replimune Group’s lead therapy, RP1, for the treatment of advanced melanoma, following a crucial endorsement from an FDA advisory committee.
On July 30, 2026, the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) convened to review the Biologics License Application (BLA) resubmission for RP1. The investigational therapy is proposed for use in combination with Bristol Myers Squibb’s PD-1 inhibitor, Opdivo (nivolumab), specifically targeting patients with advanced melanoma who have previously failed to respond to anti-PD-1 therapy alone.
The advisory panel’s discussion centered on data derived from the IGNYTE study, a single-arm phase I/II trial evaluating the RP1 and Opdivo combination. The committee focused on two primary concerns: the reliability of a single-arm study to accurately assess response rates and duration in this specific patient population, and whether the observed results demonstrated clinically meaningful systemic antitumor activity.
In a significant victory for Replimune, the panel members voted 10 to 3 in favor of the assertion that the efficacy results from the IGNYTE trial are evaluable and clinically meaningful. While the FDA is not strictly bound to follow the recommendations of its advisory committees, it historically aligns with their guidance. This positive vote significantly bolsters the prospects for RP1’s approval, with the FDA’s final decision expected by August 2, 2026.
If approved, RP1 would mark a major milestone as Replimune’s first marketed therapy. It would validate the company’s proprietary RPx platform, which utilizes an engineered strain of the herpes simplex virus designed to selectively replicate in and destroy cancer cells while stimulating a systemic anti-tumor immune response. For patients with advanced melanoma who have exhausted standard immunotherapy options, the RP1/Opdivo combination could represent a vital new line of defense.
The market reacted swiftly to the advisory panel’s endorsement. Shares of Replimune (REPL), which had experienced significant volatility over the past year, surged in pre-market trading following the announcement, reflecting investor optimism regarding the impending PDUFA decision.
The August FDA calendar is packed with other significant decisions across various indications. Also slated for review is Moderna’s mRNA-1010, an investigational mRNA-based seasonal influenza vaccine for adults aged 50 and older, which recently received unanimous backing from the Vaccines and Related Biological Products Advisory Committee. Additionally, the FDA will decide on iberdomide, an oral CELMoD from Bristol Myers Squibb, for relapsed or refractory multiple myeloma, and a novel single-tablet HIV regimen combining bictegravir and lenacapavir from Gilead Sciences.
As these PDUFA dates approach, the outcomes will not only dictate the commercial trajectories of the respective biotech firms but also signal the FDA’s current stance on emerging therapeutic modalities, including viral-based oncolytics and advanced mRNA applications. For Replimune, the favorable advisory vote is a critical hurdle cleared, setting the stage for what could be a transformative approval in the melanoma treatment landscape.
